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Background: Allergen immunotherapy (IT) is an effective treatment of respiratory allergy, 
but requires strict rules of performance. This makes compliance particularly relevant, but thus 
far only a few studies have investigated this issue.
Methods: We reviewed all the available articles on compliance and adherence with IT in its 
different forms of administration, ie, subcutaneous (SCIT), sublingual (SLIT), and local nasal 
(LNIT).
Results: Early studies, when only SCIT was available, reported a low compliance, ranging 
from 45% to 60%, but the demanding schedules used, with very frequent injections, accounted 
for this outcome, as shown by patients’ recognition of inconvenience as the major cause of 
noncompliance. The most recent studies reported a good compliance, estimated in 75% to 90%, 
to both SCIT and SLIT, inconvenience remaining the major cause of noncompliance, followed 
by cost of the treatment. The only study addressing LNIT found a very poor compliance (27%), 
the major cause being the side effects, with repeated nasal reactions to the allergen extract.
Conclusions: Adequate education of patients and optimization of administration schedules, 
with ﬁ  ne balancing between dose effectiveness and cost, are the factors most likely to achieve 
further improvement of compliance with IT.
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Introduction
Allergen immunotherapy (IT) is the practice of administering gradually increasing doses 
of the speciﬁ  c causative allergen to reduce the clinical reactivity of allergic subjects. 
IT has a central role in the management of respiratory allergy with rhinitis and asthma, 
because it is the only treatment acting on causes and not simply on symptoms as drugs 
do (Bousquet et al 1998; Frew 2003). Moreover, the capacity to alter the natural history 
of allergy offers long-lasting efﬁ  cacy once IT is discontinued (Durham et al 1999).
Subcutaneous IT (SCIT) has long been the conventional way of giving the treatment, 
but in recent years other routes of administration were introduced, mainly for safety 
reasons, and today sublingual IT (SLIT) and local nasal IT (LNIT) are suggested 
as viable treatment options when considering hyposensitization (Bousquet and van 
Cauwenberge 2001; Canonica and Passalacqua 2003).
However, IT in any form requires substantial commitment by the patients, who 
must undergo regular (usually monthly) injections when SCIT is chosen, and daily 
(or very frequent) administration of the allergen extract when SLIT is chosen, for a 
prolonged time, generally stated as at least three years. In fact, this is the minimal time 
required to achieve the immunological changes needed to ensure long-lasting clinical 
effects following the end of treatment (Frati et al 2007).
This makes compliance issues particularly relevant, but thus far little attention has 
been paid to this aspect, with only a few studies investigating compliance with SCIT 
(Cohn and Pizzi 1993; Lower et al 1993; Tinkelman et al 1995; Rhodes 1999; More and 
Hagan 2002), compliance or adherence to SLIT (Lombardi et al 2004; Pajno et al 2005; Patient Preference and Adherence 2008:2 248
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Passalacqua et al 2006, 2007), and one study investigating 
also compliance to LNIT (Pajno et al 2005).
According to established definitions, compliance is 
“The extent to which a patient’s behavior matches the 
prescriber’s advice” and adherence is “The extent to which 
the patient’s behavior matches agreed recommendations from 
the prescriber” (Haynes 1979). Measurement of adherence 
includes the number of doses actually used by the patient 
and this may result in technical problems, unless the rigid 
boundaries of a double-blind, placebo-controlled study 
are present. Of course this affects SLIT and LNIT self-
administered by patients at home, but not SCIT. The studies 
measuring adherence to SLIT approached the problem by 
contacting the patients through unscheduled phone calls, 
not leaving the time to calculate and adjusting the doses to 
please the prescriber.
Compliance to SCIT
Since SCIT is administered directly by physicians or trained 
nurses, the compliance aspects would appear of secondary 
importance, but the ﬁ  rst studies published in the 1990s 
reported rates of lack of compliance surprisingly high, 
corresponding to about 50%, in both adults (Cohn and Pizzi 
1993) and children (Lower et al 1993). The protocol used, 
based on injections at weekly interval the ﬁ  rst year and fort-
nightly interval the second year, was probably the causative 
factor for such a bad result. In particular, the study by Cohn 
and Pizzi (1993) analyzed practice records of 217 patients 
treated with SCIT for allergic rhinitis or allergic asthma 
and found that 50% of subjects with rhinitis and that 48% 
of those with rhinitis and asthma discontinued the treat-
ment. Inconvenience was identiﬁ  ed as the major cause of 
discontinuation (55% of cases) in rhinitis, while in rhinitis 
and asthma only 22% of patients indicated such an issue. 
The ﬁ  rst cause of stopping SCIT in these patients (25%) was 
feeling better with drug treatment, which was not reported 
by any patient with only rhinitis.
In the same year, the study by Lower and colleagues 
(1993) reviewed 315 patients aged 5 to 18 years who were 
prescribed SCIT for allergic rhinitis or asthma. Of them, 44% 
were noncompliant, with males slighly more compliant than 
females, and private patients more compliant than nonprivate 
patients.
In the ensuing years more favorable results were 
reported, also because of the development of less demanding 
schedules. A study evaluated SCIT-treated subjects in a 
private practice in Atlanta, USA, and found a signiﬁ  cantly 
higher compliance in patients receiving the injections in the 
allergist’s ofﬁ  ce compared to those receiving the injections 
in facilities outside the clinic, who had a noncompliance rate 
of about 35% (Tinkelman et al 1995).
A similar rate was detected in a population of 247 allergic 
patients undergoing SCIT in Mexico, who were noncompliant 
in 38% of cases. The major cause of noncompliance were 
the early feeling of improvement and the high cost of the 
treatment, but also the feeling of worsening with SCIT and 
the change to alternative medicine (Ruiz et al 1997).
Rhodes (1999) found that 12% of patients receiving 
optimal doses of allergen extracts discontinued SCIT before 
completion of the suggested three-year duration of treatment. 
The most common reasons for premature stopping were 
concurrent medical problems, inconvenience, and adverse 
reactions to treatment (Rhodes 1999). The safety issue is 
important, because it is established that to be effective SCIT 
requires the administration of sufﬁ  ciently high doses of 
allergen extracts, but this exposes the patients to the risk of 
adverse reactions (Bousquet et al 1998), which in turn may 
associate to compliance problems.
A recent study analyzed the compliance to three forms 
of IT, SCIT, SLIT, and LNIT administered in hospital or in 
private ofﬁ  ce settings in 2774 children (Pajno et al 2005). 
SCIT was used, by a build-up phase in 12 weeks followed by 
maintenance injections every 3–4 weeks, in 1886 subjects. Of 
them, 207 (10.9%) were noncompliant, with no signiﬁ  cant 
difference between the two settings. Concerning the hospital 
setting, most patients withdrew from SCIT during the build-
up phase or during the second year of treatment, while in 
private ofﬁ  ce setting most patients withdrew from SCIT after 
the ﬁ  rst year of treatment. The major reason for withdrawing 
was the cost (35%), followed by family problems (21%), 
inconvenience (20%), lack of efﬁ  cacy (16%), and adverse 
reactions (7%).
It is apparent that in the latest studies, which used 
optimal allergen extracts and less challenging schedules, 
the compliance to SCIT was much better than in previous 
investigations, both in adults (12%) and in children (11%). For 
the latter, the parents’ role in collaborating with physicians 
during the treatment must be obviously considered.
Compliance to SLIT
SLIT has different compliance issues than SCIT, because it 
is administered at home by patients themselves and thus it is 
not affected by most causes reported for noncompliance to 
SCIT, having instead compliance problems similar to drug 
treatment, which were already recognized more than thirty 
years ago (Blackwell 1973) and more recently analyzed in Patient Preference and Adherence 2008:2 249
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their relationship with patient’s characteristics, quality of 
life, and costs (Billups 2000).
In some studies not speciﬁ  cally designed for compliance 
(for instance safety and tolerability analyses) was reported 
that treatment withdrawal is frequently caused by repeated 
local reactions in the mouth or at gastrointestinal level (André 
et al 2000; Wilson et al 2005). Moreover, as previously noted 
in SCIT studies, it was observed that a lack of compliance to 
SLIT may be caused by the erroneous perception that once 
allergic symptoms are improved, SLIT is no more needed 
(Novembre et al 2004). Concerning speciﬁ  c compliance 
and adherence studies, the available data indicate quite 
satisfactory results.
In a study on 319 patients mainly addressing the efﬁ  cacy 
of SLIT, the adherence to treatment (assessed by measuring 
the consumed allergen extracts) was estimated to be good, 
ie, 80% in 72% of patients, and fair, ie, 60% in 18% of 
patients (Marogna et al 2004).
The approach of evaluating the adherence by measuring 
the consumption of allergen extracts was used in other three 
studies, which were facilitated by the fact that preparations 
in tablets or in liquid monodoses were employed. In the ﬁ  rst 
of these, adult patients under SLIT treatment were asked 
by phone (without being warned in advance) to count the 
remaining tablets in the box; the phone interview was done 
during the ﬁ  rst year in patients treated for dust mite allergy 
and during the ﬁ  rst pollen season in patients treated for 
pollen allergy. The adherence value was comprised between 
75% and 97% (Lombardi et al 2004). The other two surveys 
were real-life studies investigating the compliance to SLIT 
in 443 adult and adolescent patients (Passalacqua et al 2006) 
and in 71 children (Passalacqua et al 2007), respectively. In 
the study on adults, data on compliance were obtained (by 
unscheduled phone calls) after three months in all patients, 
while after six months data were obtained on 266 patients 
because the remaining 217 had received a preseasonal SLIT 
of 3–4 months duration; 76.3% of patients after three months 
and 74.8% after six months had a compliance higher than 
90%; in 4% of patients SLIT was discontinued for various 
reasons unrelated to treatment; and in 1% for side effects 
possibly related to treatment (Passalacqua et al 2006).
Similarly, in the study on children with the same product 
in monodoses, parents were interviewed by unscheduled 
phone calls at the third and sixth month of SLIT and 
asked to count at once the remaining doses; a compliance 
rate higher than 75% was found in 85% of children at the 
third month and in 84% of children at the sixth month; the 
major cause of withdrawal (5.6% of cases) was the cost of 
treatment, while side effects accounted for 1.4% of stopping 
(Passalacqua et al 2007).
In the already cited study on compliance to SCIT, SLIT, 
and LNIT in children, data on SLIT concerned 806 patients, 
173 of whom (21.4%) were noncompliant, with a highly 
signiﬁ  cant difference (p  0.0001) for a better compliance 
in hospital setting (90.5%) compared to private ofﬁ  ce setting 
(61.2%); the most common reason of withdrawal was the cost 
of treatment, reported globally in 36.4% of cases, followed 
by inconvenience, feeling of inefﬁ  cacy, and side effects 
(Pajno et al 2005).
Compliance to LNIT
The only study addressing this issue is that by Pajno and 
colleagues (2005) which evaluated 82 children, all treated 
in private ofﬁ  ces, and found a compliance value of 27%; 
the major reason of noncompliance to LNIT were the side 
effects, with repeated nasal reactions to introduction of the 
allergen extract reported as reason for withdrawing in 56.6% 
of cases; other causes were inefﬁ  cacy and cost, concerning 
18.3% and 13.3% of cases, respectively (Pajno et al 2005). 
By these ﬁ  ndings, the nasal route of administration, though 
scientiﬁ  cally demonstrated as effective and thus accepted in 
consensus documents (Bousquet et al 1998; Bousquet and 
van Cauwenberge 2001), seems unlikely to represent a true 
option for immunotherapy.
Comprehensive analysis 
of compliance with IT
Currently, compliance, cost, and quality of life are 
considered important issues in management of respiratory 
allergy (Blaiss 2003). From the literature on compliance 
with IT, summarized in Table 1, it is apparent that in 
early studies, when only SCIT was available, compliance 
was low, ranging from 45% to 60%, but the demanding 
schedules used, with very frequent injections, accounted 
for this outcome, as clearly shown by patients’ recognition 
of inconvenience as the major cause of noncompliance. 
Another critical aspect in compliance is patient’s knowledge 
and access to information about the treatment. A study 
from Israel showed that patients undergoing SCIT have a 
very poor knowledge of the treatment and, consequently, 
incongruous expectations. In fact, about 40% of patients 
expected a complete recovery of their allergies and about 
20% expected an improvement within days or weeks from 
starting. One fourth of the study group did not know which 
allergens were administered and one third were aware of the 
potential side effects (Sade et al 2003).Patient Preference and Adherence 2008:2 250
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Table 1 Studies on compliance with immunotherapy
Author study Kind of IT Kind of patients Compliance
Cohn and Pizzi 1993 SCIT Adults 48%
Lower et al 1993 SCIT Children 44%
Tinkelman et al 1995 SCIT Adults 65%
Ruiz et al 1997 SCIT Adults 62%
Rhodes 1999 SCIT Adults 88%
Pajno et al 2005 SCIT Children 89%
Marogna et al 2004 SLIT Adults 80%
Lombardi et al 2004 SLIT Adults (with seasonal or perennial allergies) 75%–97%
Pajno et al 2005 SLIT Children 79%
Passalacqua et al 2006 SLIT Adults and adolescents 76%
Passalacqua et al 2007 SLIT Children 85%
Pajno et al 2005 LNIT Children 27%
Abbreviations: SCIT, subcutaneous immunotherapy; SLIT, sublingual immunotherapy; LNIT, local nasal immunotherapy.
In a report on two small groups of patients undergoing 
SLIT and receiving standard instructions or a complete 
programme for education and training to SLIT, respectively, 
a lower compliance was found in the former, mainly because 
of common local side effects (oral itching and burning, 
abdominal pain) they were not able to manage (Incorvaia 
et al 2003).
Analyzing the most recent studies, one may think that 
patient’s information on IT, in both its subcutaneous and 
sublingual forms of administration, is improved, because a 
good compliance, estimated in 75% to 90%, was reported. 
Considering SLIT in children, sociological factors, such as 
the educational and economic status of the family, should 
be taken in consideration when prescribing the treatment, 
because successful adherence is dependent on the parents’ 
understanding and motivation.
Also in recent studies the two major causes of 
noncompliance were inconvenience – in SCIT, it was the 
need to go to hospital or to the physician’s ofﬁ  ce to have 
the shots and in SLIT, it was the need of very frequent 
administrations – and cost. Concerning SLIT, which was 
introduced much more recently in respect to SCIT, it is likely 
that the individuation of optimal dosage and the modiﬁ  cations 
of current schedule may favor a further improvement of 
compliance and adherence. For example, it was recently 
demonstrated that in patients treated with SLIT for dust 
mite allergy, an intermittent schedule, while maintaining 
comparable efﬁ  cacy and safety, had a better compliance than 
the usual continuous schedule (Cadario et al 2008).
Conclusive considerations on compliance with SLIT 
must take into account a comparison with antiallergic 
drugs, which seems particularly appropriate for topically 
administered preparations. For example, adherence rates to 
prescribed inhaled drugs in asthma are surely problematic, 
corresponding to a range from 30% to 70% in general 
(Bender et al 1997), with a rate lower than 50% in children 
(Milgrom et al 1996). Compliance with SLIT is much better 
and is likely to further improve following the approaching 
introduction of more friendly preparations in tablets and 
expanding patient’s knowledge and education.
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